Pharma Research has secured a $160 million investment through redeemable convertible preference shares (RCPS) issuance from European global private equity firm CVC, establishing a vital platform for global market expansion.

This strategic partnership with CVC, a leading European fund managing approximately $230 billion, will accelerate Pharma Research's entry into international markets. CVC's investment represents a significant endorsement of Pharma Research’s potential, as the firm has a successful track record in healthcare investments across Europe and other global markets.

Pharma Research will leverage CVC's extensive network and market expertise to expand its operations more effectively and reliably overseas. This includes establishing subsidiaries in key markets and offering tailored services to expand its global market share and meet diverse consumer needs.

CVC's collaboration will play a crucial role in enhancing Pharma Research’s strategy for global penetration, providing necessary resources and network support. The funds from this investment are prioritized for strategic international mergers and acquisitions.

Moreover, Pharma Research plans to significantly boost its R&D investments, focusing on the development of new products and the enhancement of existing ones to increase its competitiveness on the global stage and continue acquiring innovative technologies.

With CVC’s robust experience in the global healthcare sector, Pharma Research is expected to deliver differentiated value to global customers, reinforcing its position in the global market and focusing on delivering innovative products and services.

CVC’s commitment is seen as a pivotal support for Pharma Research to solidify its presence in the global market and drive sustainable growth, aiming to deliver high value to its customers and shareholders as a global leader.